Navigation Links
Xlumena Announces Initial Commercial Use of its First-in-Class AXIOS Stent and Delivery System for Treatment of Pancreatic Pseudocysts and Fluid Collections
Date:1/9/2014

MOUNTAIN VIEW, Calif., Jan. 9, 2014 /PRNewswire/ -- Xlumena, Inc., a leader in advanced endoscopic devices, today announced the first US commercial use of its AXIOS Stent and Delivery System (AXIOS) at California Pacific Medical Center (CPMC) in San Francisco.  The recent FDA clearance of AXIOS represents a significant breakthrough in the treatment of patients with pancreatic pseudocysts and fluid collections.

There are more than 90,000 cases of pseudocysts and pancreatic fluid collections in the US each year and the global market is estimated to be greater than $200 million annually.  Prior to the FDA clearance of AXIOS last month, physicians had no "on-label" options for treating these conditions.  According to Christy Foreman, director of the Office of Device Evaluation at the FDA, "the AXIOS Stent provides a new option for physicians to effectively treat pseudocysts."

AXIOS is the first stent specifically designed for treatment of a pancreatic pseudocyst or fluid collection.   Its design allows for rapid drainage of these fluid collections, which are often filled with thick, infected or necrotic content.

"I'm delighted that we now have an anastomotic stent that was designed specifically for drainage of pancreatic fluid collections," said Dr. Kenneth Binmoeller, Founder and Chief Medical Officer of Xlumena.   Following FDA clearance of AXIOS, Dr. Binmoeller performed the first drainage of a pancreatic pseudocyst with AXIOS at CPMC.  "After AXIOS placement, we were able to clear out debris from the cyst with the endoscope, which led to immediate improvement of the patient's clinical course."  

Having just closed a $25M Series C financing, Xlumena is expanding to meet the demand for AXIOS, initiating a targeted launch in selected centers of excellence across the US. AXIOS is the first in a family of devices that Xlumena plans to bring to the US market to address significant clinical needs in the field of interventional endoscopy.  Already CE marked and used in rapidly growing numbers is the next-generation HOT AXIOS, which incorporates cautery into the delivery of the AXIOS stent and is currently used in Europe for the treatment of pancreatic pseudocysts, acute cholecystitis and biliary obstruction.

CAUTION: The HOT AXIOS and AXIOS devices for the gallbladder and bile duct have CE mark designation in Europe. They are not available for sale in the United States. 

For more information about the AXIOS Stent and Delivery System, please visit www.xlumena.com.

About Xlumena, Inc.: Xlumena is the leader in developing products that enable advanced, image-guided endoscopy procedures. These innovations will allow endoscopists to offer minimally invasive alternatives to patients suffering from common gastrointestinal and biliary conditions. Pioneering interventional endoscopists around the world are using Xlumena's products to extend their therapeutic reach. 

Video with caption: "AXIOS Stent and Delivery System Procedure Animation". Video available at: http://origin-qps.onstreammedia.com/origin/multivu_archive/PRNA/ENR/FX-SF43594-20140109-1.mp4

Contact:
Joni Cronin
650-961-9900
jcronin@xlumena.com


'/>"/>
SOURCE Xlumena, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Xlumena Closes Series C Financing; Focuses on Expanding Global Commercial Presence and Obtaining FDA Clearance
2. EndoChoice Announces Investigator-Initiated Study Program for Fuse Endoscopy System
3. Altheus Therapeutics announces completed enrollment of ZA201, a Phase 2 clinical trial of Zoenasa for distal ulcerative colitis
4. Akili Interactive Labs Announces Partnership with Pfizer to Test Video Game in People at Risk of Alzheimers Disease
5. Endo Announces Divestiture Of HealthTronics
6. The MED Group Announces Agreement with Golden Technologies
7. BioSpecifics Technologies Corp. Announces Positive Top-line Data from Phase 2 Clinical Trial of CCH for the Treatment of Human Lipoma
8. Kalila Medical Announces CE Mark Approval For The Vado Steerable Sheath Used During Atrial Fibrillation Procedures
9. Navigating Cancer Announces Milestones Related to Patient Education Program
10. TRICAST Announces Patent-Pending Technology for Real-Time Health Data Analysis
11. Orexigen Announces June 10, 2014 PDUFA Action Date for Contrave
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016 Worldwide Radiology ... significant growth as next generation systems provide a ... radiology for cancer surgery. New systems pinpoint the ... that has been such a problem previously, limiting ... Radiosurgery robots take cancer surgery far beyond what ...
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... Summary Global Markets Direct,s, ,Wegener Polyangiitis - ... the Wegener Polyangiitis,s therapeutic pipeline. This report ... Wegener Polyangiitis, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ...
(Date:2/4/2016)... , Feb. 4, 2016 Global ... competitive market to drive long-term market growth ... common set of chronic disorders that affect 5–7% ... in terms of their symptoms and key patient ... dysregulation of immune pathways and an inappropriate immune ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... 08, 2016 , ... Joshua Rosenthal, PhD, Chief Scientific Officer ... use newly released government data on populations and physicians to better calculate risk ... the value they create to succeed in new economic models for value based ...
(Date:2/8/2016)... ... February 08, 2016 , ... The schedule is now online for ... 2016 Conference, which is being held May 25-29 at the Loews Chicago O’Hare Hotel, ... interventions and causes of chronic illness in children. , Very recent articles have cited ...
(Date:2/7/2016)... Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... ... ... ability to correct pelvic organ prolapse with the latest techniques and the most ... greatest risk for pelvic organ prolapse, particularly after menopause. Other risk factors include ...
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart Holdings, Inc. ... organizations with the tools and information to lower the costs, and increase the ... cost of providing employee healthcare benefits by as much as 22%:, + ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT:     , This ... an estimated 5000 perioperative nurses in attendance to study the latest evidence-based ...
Breaking Medicine News(10 mins):